Clinical trials: Infarction
Coronary Artery Disease
Ranolazine Loading to Prevent PCI-induced Myocardial Injury
It has previously been shown that pretreatment with ranolazine 1,000 mg twice daily for 7 days can significantly reduce procedural myocardial injury in elective percutaneous coronary intervention (PCI).
- Trial name
- TWILIGHT (NCT01491061)
- Testing
- Ranolazine
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Roma La Sapienza
Sickle Cell Disease
Aspirin Prophylaxis in Sickle Cell Disease
Neurologic complications secondary to cerebrovascular damage are prevalent in children with sickle cell disease. These patients experience both clinically overt cerebrovascular accidents and "silent infarctions" demonstrated by…
- Trial name
- START (NCT00178464)
- Testing
- aspirin
- Volunteers
- 11 people
- Sponsor
- University of Rochester
Acute Myocardial Infarction
Validation of a High-risk Versus Low-risk Referral Model in Suspected Acute Coronary Syndrome
In Emergency Departments patients admitted with chest pain may suffer from non-significant to lifethreatening conditions. The aim of the present study is to develop and validate a referral model in chest pain patients which…
- Trial name
- NCT01747421
- Where
- Denmark
- Volunteers
- 495 people
- Sponsor
- University of Southern Denmark
Cardiovascular Disease
Supporting Post Myocardial Infarction (MI) Risk Modification Intervention Via Telemedicine Evaluation
The study is a three-arm design where up to 600 patients hospitalized post-MI are recruited from a large hospital and randomized to either the education group (control group) or one of the two intervention groups.
- Trial name
- SPRITE (NCT00901277)
- Testing
- web intervention, nurse intervention
- Volunteers
- 416 people
- Sponsor
- Duke University
Atherosclerosis, Heart Failure, Congestive
The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function
The renin angiotensin system (RAS) plays an important physiological and pathophysiological role in the control of blood pressure and plasma volume.
- Conditions
- Atherosclerosis, Heart Failure, Congestive, Hypertension, Myocardial Infarction
- Trial name
- NCT00001628
- Testing
- Angiotensin II type 1 receptor antagonists
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Aortic Stenosis, Cardiogenic Shock
Transcatheter AortiC Valve Implantation in aorTic stenosIs CardiogenIc Shock
The goal of this clinical trial is to learn if acute transcatheter aortic valve implantation (TAVI) is superior to standard treatment (stabilization in an intensive care unit and TAVI subsequently) to treat cardiogenic shock in…
- Trial name
- TACTICS (NCT06638268)
- Testing
- Acute TAVI, Stabilization and subacute TAVI
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Takotsubo Cardiomyopathy, Myocardial Infarction
Establishing the Incidence of Tako-tsubo Cardiomyopathy in Scotland
Acute stress-induced (Takotsubo cardiomyopathy) presents like a heart attack and is triggered by intense emotional or physical stress.
- Trial name
- STARR (NCT03299569)
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- University of Aberdeen
Coronary Artery Disease, Stable Angina
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
Prospective, multi-center, registry designed to enrol up to 2,000 patients in up to 35 International centers. All patients will receive a BioMatrix AlphaTM stent as per clinical practice and will be followed for 2 years for data…
- Conditions
- Coronary Artery Disease, Stable Angina, Ischemia, Acute Coronary Syndrome
- Trial name
- NCT02871622
- Testing
- BioMatrix AlphaTM
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Biosensors Europe SA
Acute Myocardial Infarction, Revascularization
Long Term Predictors of Acute Myocardial Infarction in Patients With Coronary Revascularization
Worldwide, Ischemic heart disease is the single most common fatal disease. One of the most common causes of acute myocardial infarction is represented by obesity.
- Trial name
- NCT06546228
- Testing
- No intervention. Only observational.
- Where
- Italy
- Volunteers
- 652 people
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico "G. Martino"
Myocardial Infarction
APRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3
Reocclusion of the infarct artery is observed in about 30% of patients within three months after successful thrombolysis for acute myocardial infarction (MI).
- Trial name
- NCT00138034
- Testing
- Percutaneous coronary intervention (PCI)
- Where
- Netherlands
- Volunteers
- 49 people
- Sponsor
- Heartcenter, University Medical Center St. Radboud
Coronary Heart Disease
Peking University & University of Michigan Study of MI and Atherosclerosis
Coronary heart disease and myocardial infarction have become a major threat to the health of our people. Their incidence rate and mortality rate are still rising. Dyslipidemia is one of the important risk factors.
- Trial name
- PUUMA (NCT04950699)
- Testing
- Single-nucleotide Polymorphism of genes related with Dyslipidemia
- Volunteers
- 4,700 people
- Sponsor
- Peking University Third Hospital
Heart Diseases, ASD - Atrial Septal Defect
Abbott Structural Heart Device Registry
The Abbott Structural Heart (SH) Registry is being conducted to confirm the safety and performance of Abbott's SH devices in a post-market, real-world setting.
- Conditions
- Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale
- Trial name
- SH-Registry (NCT06590467)
- Testing
- Amplatzer™ Occlusion Devices, Epic™ Surgical Tissue Heart Valve devices
- Where
- 36 sites in United States, Denmark and 8 more
- Volunteers
- 2,500 people
- Sponsor
- Abbott Medical Devices
Myocardial Infarction, Acute, Myocardial Ischemia
Determining the Mechanism of Myocardial Injury and Role of Coronary Disease in Type 2 Myocardial Infarction
Myocardial injury is common in patients without acute coronary syndrome, and therefore international guidelines propose a classification of patients with myocardial infarction by aetiology.
- Conditions
- Myocardial Infarction, Acute, Myocardial Ischemia, Myocardial Injury
- Trial name
- DEMAND-MI (NCT03338504)
- Testing
- Invasive coronary angiography, CT coronary angiography, Cardiac MRI
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- University of Edinburgh
Cardiogenic Shock
Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial
The primary objective of this study is to assess reasonable safety and performance of the HeartMate PHP to provide hemodynamic support for up to 72 hours in patients with cardiogenic shock requiring stabilization.
- Trial name
- NCT02279979
- Testing
- HeartMate PHP
- Where
- 6 sites in Czechia, Germany and 2 more
- Volunteers
- 9 people
- Sponsor
- Abbott Medical Devices
Cardiogenic Shock, Acute Decompensated Heart Failure
Study of Patients Admitted to a Cardiac Intensive Care Unit With Acute CardioVascular Disease
This is a registry of the patients that are admitted to CICU and treated by the Scientific Staff of the 2nd Department of Cardiology, due to an acute cardiovascular disease (acute coronary syndrome, acute heart failure…
- Conditions
- Cardiogenic Shock, Acute Decompensated Heart Failure, Acute Pulmonary Embolism, Acute Myocardial Infarction
- Trial name
- NCT06081205
- Testing
- Admission in the Cardiac Intensive Care Unit (CICU)
- Where
- Greece
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Ioannina
Myocardial Infarction
Early Versus Late Loading of Ticagrelol in Patients With STEMI
Current guidelines recommend percutaneous coronary intervention (PCI) for most patients with ST segment elevation acute myocardial infarction (STEMI) or with non ST segment elevation acute coronary syndrome (NSTEACS) .
- Trial name
- NCT04267224
- Testing
- Ticagrelor 90mg
- Volunteers
- 800 people
- Sponsor
- Assiut University
Acute Coronary Syndrome
STEMI Versus NSTEMI: Clinical and Angiographic Differences
The purpose of this study is to assess differences in the risk profile and in the coronary angiographic presentation between STEMI and NSTEMI.
- Trial name
- NCT01636427
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Federico II University
Mitral Regurgitation
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant
Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups).
- Trial name
- STAR-TEER Ⅰ (NCT06901466)
- Testing
- Experimental: Rivaroxaban monotherapy, Active Comparator: Rivaroxaban+Clopidogrel
- Where
- China
- Volunteers
- 880 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Hypertension, Dementia
BedMed-Frail: Does the Potential Benefit of Bedtime Antihypertensive Prescribing Extend to Frail Populations?
High blood pressure (present in 1 of 5 Canadian adults) increases the risk of heart attack and stroke. Blood pressure lowering pills reduce this risk - but perhaps not optimally.
- Trial name
- NCT04054648
- Testing
- Bedtime administration of the participant's pre-existing antihypertensive medications
- Where
- Canada
- Volunteers
- 776 people
- Sponsor
- University of Alberta
Prostate Cancer, Cardiovascular Death
Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy
The purpose of this study is to review cause of death in patients undergoing prostate brachytherapy at a single institution. Furthermore, we are analyzing patients undergoing androgen deprivation therapy and whether or not this…
- Trial name
- NCT00651222
- Testing
- No intervention was required
- Where
- United States
- Sponsor
- Prostate Cancer Foundation of Chicago